NTHI NEONC TECHNOLOGIES HOLDINGS...

Nasdaq neonctech.com


$ 6.17 $ 0.11 (1.85 %)    

Friday, 21-Nov-2025 11:35:54 EST
QQQ $ 589.20 $ 1.87 (0.32 %)
DIA $ 462.86 $ 3.39 (0.74 %)
SPY $ 658.71 $ 3.70 (0.56 %)
TLT $ 89.37 $ -0.29 (-0.32 %)
GLD $ 376.51 $ 2.51 (0.67 %)
$ 5.93
$ 5.95
$ 6.25 x 2,000
$ 6.50 x 70
$ 5.75 - $ 6.08
$ 3.20 - $ 25.00
38,069
na
113.93M
$ -0.31
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2025 09-30-2025 10-Q
2 08-18-2025 06-30-2025 10-Q
3 05-09-2025 03-31-2025 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
NeOnc Technologies Q3 EPS $(0.45)
11/14/2025 21:04:54

Core News & Articles

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biop...

Core News & Articles

NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi–Phase 2 clinical-stage biopharmace...

Core News & Articles

NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmace...

Core News & Articles

NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmace...

Core News & Articles

NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmace...

Core News & Articles

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biop...

Core News & Articles

NeOnc Technologies (NASDAQ:NTHI) reported quarterly losses of $(0.30) per share. This is a 11.11 percent decrease over losses o...

Core News & Articles

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for ...

Core News & Articles

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi–Phase 2 clinical-stage biotechnology company focused on breakthrough t...

Core News & Articles

-SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION